乌司奴单抗与TNF抑制剂在银屑病或银屑病关节炎患者中的房颤及心血管事件风险比较
结果显示乌司奴单抗组房颤校正风险比1.08(95%CI 0.76-1.54)、MACE为1.10(95%CI 0.80-1.52),与TNF抑制剂相比未见明显差异。
要点
- 乌司奴单抗与TNF抑制剂相比,新发房颤风险无实质差异(aHR 1.08,95%CI 0.76-1.54)。
- MACE风险同样无实质差异(aHR 1.10,95%CI 0.80-1.52)。
- 选择系统性治疗时,可将两者心血管安全性视为相近参考。
核心结论
- 在银屑病或银屑病关节炎患者中,启用乌司奴单抗与TNF抑制剂后新发房颤或MACE的风险未见实质差异。
- 该信息有助于权衡不同系统性治疗策略的风险与获益。
研究设计与样本
- 队列研究,数据来自美国两个商业保险数据库(Optum与MarketScan),时间跨度2009年9月25日至2015年9月30日。
- 排除基线期有房颤史或使用抗心律失常药或抗凝药者。
主要发现
- 房颤粗发生率:乌司奴单抗组5.0/1000人年(95%CI 3.8-6.5),TNF抑制剂组4.7/1000人年(95%CI 4.2-5.2)。
- MACE粗发生率:乌司奴单抗组6.2/1000人年(95%CI 4.9-7.8),TNF抑制剂组6.1/1000人年(95%CI 5.5-6.7)。
- 合并校正后,乌司奴单抗组新发房颤的HR为1.08(95%CI 0.76-1.54),MACE的HR为1.10(95%CI 0.80-1.52),均以TNF抑制剂为参照。
关键数值与推荐
- 主要结局为新发房颤与MACE(包括心肌梗死、卒中或冠状动脉血运重建)。
- 房颤与MACE风险比较均采用校正后风险比,以TNF抑制剂初始治疗者为参照。
- 粗发生率以每1000人年报告,并给出95%CI。
临床怎么用
- 对于银屑病或银屑病关节炎患者,乌司奴单抗与TNF抑制剂在房颤及MACE风险上未见实质差异,可作为系统性治疗心血管安全性权衡的参考。
- 存在心血管风险的患者选择生物制剂时,可结合该比较证据与个体情况综合决策。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accumulating evidence indicates that there is an increased risk of cardiovascular disease among patients with psoriatic disease. Although an emerging concern that the risk of atrial fibrillation (AF) may also be higher in this patient population adds to the growing support of initiating early interventions to control systemic inflammation, evidence on the comparative cardiovascular safety of current biologic treatments remains limited. OBJECTIVE: To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included data from a nationwide sample of 78 162 commercially insured patients in 2 US commercial insurance databases (Optum and MarketScan) from September 25, 2009, through September 30, 2015. Patients were included if they were 18 years or older, had psoriasis or psoriatic arthritis, and initiated ustekinumab or a TNFi therapy. Exclusion criteria included history of AF or receipt of antiarrhythmic or anticoagulant therapy during the baseline period. EXPOSURES: Initiation of ustekinumab vs TNFi therapy. MAIN OUTCOMES AND MEASURES: Incident AF and MACE, including myocardial infarction, stroke, or coronary revascularization. RESULTS: A total of 60 028 patients with psoriasis or psoriatic arthritis (9071 ustekinumab initiators and 50 957 TNFi initiators) were included in the analyses. The mean (SD) age was 46 (13) years in Optum and 47 (13) in MarketScan, and 29 495 (49.1%) were male. Overall crude incidence rates (reported per 1000 person-years) for AF were 5.0 (95% CI, 3.8-6.5) for ustekinumab initiators and 4.7 (95% CI, 4.2-5.2) for TNFi initiators, and for MACE were 6.2 (95% CI, 4.9-7.8) for ustekinumab initiators and 6.1 (95% CI, 5.5-6.7) for TNFi initiators. The combined adjusted hazard ratio for incident AF among ustekinumab initiators was 1.08 (95% CI, 0.76-1.54) and for MACE among ustekinumab initiators was 1.10 (95% CI, 0.80-1.52) compared with TNFi initiators. CONCLUSIONS AND RELEVANCE: No substantially different risk of incident AF or MACE after initiation of ustekinumab vs TNFi was observed in this study. This information may be helpful when weighing the risks and benefits of various systemic treatment strategies for psoriatic disease.
引用
- Lee MP, Desai RJ, Jin Y, et al. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatol. 2019. PMID: 30916734. doi:10.1001/jamadermatol.2019.0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。